G2GBIO

G2GBIO Inc., a clinical-stage biotech company provides pharmaceutical products. The company's pipeline products include GB-5001, GB-5001A, and GB-5112 for the treatment of Alzheimer's disease.

Its portfolio also includes GB-6002, an opioid drug that is used for post-operative pain treatment, GB-7001 for type-2 diabetes treatments, GB-5313 for the treatment of Osteoarthritis, GB-7101 and GB-7103 for the treatment of prostate cancer, GB-6201 and GB-6203 for androgenetic alopecia treatments, and GH-001 for the treatment of Hepatitis B. It also develops GB-2001 for animal castration GB-2006, an animal postoperative pain relief drug, which is in clinical trial stage. Founded in 2017, the company is headquartered in Cheongju-si, South Korea.